Verition Fund Management
MDNA

Verition Fund Management’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Verition Fund Management’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-555,392
Closed -$159K – 2815
2023
Q3 		$159K Sell
555,392
-34,108
-6% -$13.3K ﹤0.01% 2037
2023
Q2 		$282K Sell
589,500
-13,907
-2% -$8.6K ﹤0.01% 1603
2023
Q1 		$392K Buy
603,407
+64,356
+12% +$40.1K 0.01% 1377
2022
Q4 		$253K Hold
539,051
– – ﹤0.01% 1603
2022
Q3 		$447K Hold
539,051
– – 0.01% 1972
2022
Q2 		$631K Hold
539,051
– – 0.01% 1298
2022
Q1 		$685K Hold
539,051
– – 0.01% 1713
2021
Q4 		$879K Hold
539,051
– – 0.01% 1381
2021
Q3 		$1.49M Hold
539,051
– – 0.01% 773
2021
Q2 		$1.62M Hold
539,051
– – 0.01% 612
2021
Q1 		$2.2M Sell
539,051
-600
-0.1% -$2.44K 0.02% 390
2020
Q4 		$2.53M Buy
+539,651
New +$2.17M 0.02% 335

Other funds holding MDNA

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
NDSI
Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Verition Fund Management's MDNA Position: Q4 2023 in Review

Verition Fund Management sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 555,392 shares — an estimated $159K sold.

Verition Fund Management first reported a position in MDNA in Q4 2020 and held it in 12 quarters. The position peaked at $2.53M in Q4 2020. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

  • Verition Fund Management reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
  • Verition Fund Management sold 555,392 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $159K.
  • Verition Fund Management first reported a position in Medicenna Therapeutics Corp. Common Shares in Q4 2020 and held it in 12 quarters.
  • Verition Fund Management's Medicenna Therapeutics Corp. Common Shares position peaked at $2.53M in Q4 2020.
  • 3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Verition Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.